Progressive Retinal Atrophy: An Overview
Progressive retinal atrophy (PRA) is not a single disease but a family of inherited eye conditions that share a common endpoint: the progressive degeneration of photoreceptor cells in the retina, leading to visual impairment and ultimately complete blindness. For herding breed owners and breeders, PRA represents one of the most important genetic health challenges because it affects some of the most capable and widely bred working dogs, including Border Collies, Collies, Australian Shepherds, and Welsh Corgis.
The tragedy of PRA lies in its timeline. Affected dogs typically begin losing vision in dim light during middle age, a phenomenon owners often first notice as reluctance to navigate dark rooms or hesitation on stairs at night. This night blindness gradually progresses to daytime vision loss over months to years, with most affected individuals reaching complete blindness by the time they are seven to ten years old. By the time clinical signs appear, many affected dogs have already been used in breeding programs, potentially passing the responsible alleles to another generation.
This is precisely why genetic testing is so valuable: it identifies carriers and affected individuals long before any clinical signs develop. Our comprehensive guide to canine DNA testing provides an overview of how to choose testing laboratories and interpret results, which applies directly to PRA screening.
The Photoreceptor Cells and Why They Fail
The retina is a thin layer of neural tissue lining the back of the eye, containing two types of photoreceptor cells: rods and cones. Rod cells are responsible for vision in low light conditions, while cone cells handle daylight vision and color discrimination. In most forms of PRA, rod cells begin to degenerate first, which explains why night blindness is typically the earliest symptom.
The underlying biology varies between the different genetic forms of PRA, but common themes emerge. Many PRA mutations affect genes encoding proteins essential for the phototransduction cascade, the molecular chain of events that converts light energy into electrical signals the brain can interpret. Others affect genes involved in the structural maintenance of photoreceptor outer segments, the specialized cellular compartments that contain the light-absorbing proteins.
Once photoreceptors begin to die, the process is currently irreversible. Research into gene therapy approaches for canine PRA has shown promising results in laboratory settings, and some trials have demonstrated partial vision restoration in affected dogs treated early in the disease course. However, these treatments are not yet widely available, making prevention through genetic testing the most practical strategy.
Genetic Forms of PRA in Herding Breeds
prcd-PRA (Progressive Rod-Cone Degeneration)
The prcd form is the most widespread type across dog breeds generally and affects several herding breeds including Collies, Australian Cattle Dogs, and Nova Scotia Duck Tolling Retrievers. The causal mutation is a variant in the PRCD gene on chromosome 9. Inheritance is autosomal recessive: a dog must inherit two copies of the mutant allele to be affected. Single-copy carriers are visually normal throughout their lives.
A particularly important genetic subtlety affects prcd-PRA testing interpretation. In some breeds, rare modifier loci can influence whether a homozygous mutant dog actually develops the disease. This means that a prcd clear/clear result is definitive — the dog cannot develop this form of PRA — but a homozygous affected result does not guarantee disease development with absolute certainty across all breed contexts. For breeding decisions, this nuance matters: affected dogs should not be bred, but the prognostic implications for an individual affected pet warrant discussion with a veterinary ophthalmologist.
Rcd3-PRA (Rod-Cone Dysplasia Type 3)
Rod-cone dysplasia type 3 affects Cardigan Welsh Corgis and results from a mutation in the PDE6A gene, which encodes a subunit of the phosphodiesterase enzyme central to the phototransduction cascade. Rcd3 is also autosomal recessive. Unlike prcd, which causes gradual degeneration, rcd3 causes abnormal development of photoreceptors from birth, with affected dogs showing significant vision impairment in early puppyhood.
Because of this early onset, rcd3-affected Cardigans may be identifiable to experienced breeders from their littermates’ behavior before testing age. However, carriers are indistinguishable from clear dogs without genetic testing, making routine screening of all breeding Cardigans essential.
Erd-PRA (Early Retinal Degeneration)
Norwegian Elkhounds and mixed-breed dogs with Elkhound ancestry are susceptible to early retinal degeneration, caused by a mutation in the STK38L gene. While Elkhounds are not a traditional herding breed, they share herding dog genomic ancestry and occasionally appear in mixed working dog contexts.
CEA-Associated Retinal Changes
Collie eye anomaly (CEA) is a distinct condition from PRA but deserves mention here because it affects many of the same herding breeds — Rough and Smooth Collies, Border Collies, Australian Shepherds, and Shetland Sheepdogs. CEA involves abnormal development of the choroid, the vascular layer beneath the retina, and in its severe form can include retinal detachment and blindness. CEA is caused by a deletion in the NHEJ1 gene on chromosome 37. Breeders working with these breeds should test for both PRA and CEA, as a dog can carry mutations for multiple eye conditions simultaneously.
The Role of the OPHTHALMOLOGIC Examination
Genetic testing and veterinary ophthalmologic examination are complementary, not interchangeable. A clear DNA test result for known PRA mutations does not rule out atypical forms of PRA that lack characterized mutations, nor does it detect other retinal abnormalities unrelated to tested mutations. Annual eye examinations by a board-certified veterinary ophthalmologist, with results registered in breed health databases, provide a clinical check that catches conditions genetic tests cannot identify.
Conversely, ophthalmologic examinations cannot reliably distinguish carriers from clear dogs for recessive conditions, and cannot predict future disease development in genetically at-risk individuals. The two approaches together provide a more complete picture than either alone.
Breeding dogs should ideally have current eye certifications from both sources. Several registry systems, including CAER in North America and KC/BVA schemes in the UK, maintain databases of eye examination results that breeders can search when evaluating potential mates.
Population-Level Allele Frequencies
Understanding how common PRA carrier status is within specific herding breed populations helps breeders assess the practical challenge they face. Published data from breed health surveys and genetic testing laboratories provide rough estimates of carrier frequencies.
In Collies, prcd carrier frequencies have historically been reported at around 10-15% in some population samples, though this varies by regional population and has changed over time as testing has become more common. In Australian Shepherds, the picture is complicated by the breed’s genetic diversity and the presence of multiple PRA variants that have not yet been fully characterized.
These allele frequencies mean that random matings within an untested population carry meaningful risk of producing affected offspring. If 12% of dogs in a breed are prcd carriers, a random mating between two untested dogs carries approximately a 0.36% chance of producing affected puppies (0.12 × 0.12 × 0.25). Across many litters and many breeders in a breed, this translates to a significant number of affected dogs born annually — most of which could be prevented with routine testing.
Breeding Strategies for PRA Elimination
The standard recommendation for managing recessive disease alleles in breeding programs is the carrier-to-clear strategy:
Affected × affected: Never appropriate. All offspring will be affected.
Affected × clear: All offspring will be carriers. Never recommended except in rare conservation contexts where no other option exists.
Carrier × carrier: 25% chance of affected, 50% chance of carriers, 25% chance of clears. Should be avoided.
Carrier × clear: 50% chance of carriers, 50% chance of clears. No affected offspring. Acceptable when a carrier dog has other attributes that justify its inclusion in the breeding program, such as outstanding working ability, health in other areas, or important genetic diversity.
Clear × clear: All offspring clear. Ideal from a PRA standpoint.
The critical principle is that carrier dogs should not be eliminated from breeding populations without careful consideration of the genetic diversity they carry. Removing all carriers from a breed with already limited genetic diversity could create a genetic bottleneck, concentrating other recessive alleles and reducing overall population health. The goal is systematic reduction of the disease allele frequency over generations through the carrier × clear strategy, not abrupt elimination.
This is directly connected to the inbreeding coefficient considerations that responsible breeders must balance alongside disease allele management. A clear-of-PRA dog that is closely related to every other dog in the breeding pool may represent a worse choice overall than a PRA carrier with valuable genetic diversity.
Emerging Research and Novel Mutations
The catalog of identified PRA mutations in dogs continues to grow as whole-genome sequencing becomes more accessible and breed health initiatives fund large-scale studies. New forms of PRA affecting herding breeds are periodically characterized, sometimes in breeds that breeders assumed had no significant PRA burden.
This evolving landscape has two important implications. First, a negative DNA test result for currently characterized PRA mutations does not confer absolute protection against all forms of PRA, only those specific mutations that were tested. Second, breeders and breed health committees should support the banking of DNA from affected dogs to facilitate identification of novel causative mutations.
The intersection of PRA research with broader canine genomics is also yielding insights into retinal biology that may have applications in human medicine. Advances in canine genomic medicine increasingly include the retinal diseases, where the dog’s eye anatomy closely resembles the human eye and makes canine PRA a powerful natural model for developing treatments applicable to human retinal dystrophies.
Practical Recommendations for Herding Breed Owners
For breeders: Test all breeding stock for PRA mutations relevant to the specific breed before their first litter. Make results publicly available through breed health databases. Prioritize clear × clear or clear × carrier pairings and commit to reducing the carrier proportion in your program over time.
For puppy buyers: Ask to see PRA test results for both parents before purchasing a puppy. A breeder who tests consistently and makes results available is demonstrating a commitment to the long-term health of their dogs.
For owners of adult dogs: If your dog begins showing signs of visual difficulty, particularly in low-light conditions, seek a veterinary ophthalmologic evaluation promptly. Early identification, even without a treatment that reverses the process, allows you to prepare your home environment and management routines to support a dog that is losing vision.
The elimination of inherited blindness from herding breeds is achievable. The genetic tools exist, the testing infrastructure is in place, and the precedent set by breeds that have dramatically reduced PRA prevalence through systematic testing demonstrates that the goal is realistic. It requires sustained commitment from breeders across generations — precisely the kind of long-term thinking that defines responsible stewardship of these extraordinary working breeds.